NCT06785636 - Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617 | Biotech Hunter

Enrollment

252

Participants

Timeline

Start Date

February 7, 2025

Primary Completion Date

June 30, 2028

Study Completion Date

April 30, 2029

Conditions

mCRPC (Metastatic Castration-resistant Prostate Cancer)Genital Neoplasms, MaleUrogenital NeoplasmsUrogenital CancersProstatic DiseasesProstatic NeoplasmsMale Urogenital DiseasesNeoplasmsNeoplasms by SiteProstate Cancer

Interventions

DRUG

Pocenbrodib

Pocenbrodib is a selective oral inhibitor of CBP/p300 bromodomain interaction with acetylated lysines on histones.

DRUG

Cohort 2A (Pocenbrodib monotherapy), Cohort 2B (Pocenbrodib + abiraterone acetate), Cohort 2C (Pocenbrodib + olaparib), Cohort 2D (Pocenbrodib + 177Lu-PSMA-617

Pocenbrodib alone or in combination

Trial Locations (8)

22031

RECRUITING

NEXT Oncology - Virginia, Fairfax

27710

RECRUITING

Duke University medical center, Durham

33140

RECRUITING

Mount Sinai Medical Center, Miami

48201

RECRUITING

Karmanos cancer institute, Detroit

63108

RECRUITING

Siteman Cancer Center, St Louis

68130

RECRUITING

Nebraska Cancer Specialists, Omaha

77030

RECRUITING

Oncology Consultants, P.A, Houston

80045

RECRUITING

University of Colorado Health, Aurora